Integrated analysis of metabolomics combined and net-work pharmacology reveals the effects of dexmedetomidine on early postoperative cognitive dysfunction in elderly patients: randomized controlled trial.

ABSTRACT:

Background

Postoperative cognitive dysfunction (POCD) negatively impacts patients' post-surgery recovery, and, in severe cases, raises the risk of mortality. Nonetheless, the underlying mechanism of POCD remains incompletely elucidated, and there is a notable dearth of effective treatment strategies.

Methods

A randomized allocation was conducted among a total of 90 patients who underwent arthroplasty surgery, with 45 patients assigned to the dexmedetomidine group and 45 patients assigned to the control group. The Dexmedetomidine (DEX) group received an intravenous infusion of 1 µg/kg dexmedetomidine for 10 min, followed by a maintenance dose of 0.4 µg/kg/h for 30 min before surgery completion; the control (CON) group received 0.9% normal saline, which was continuously pumped

SUBMITTER: Du Y 

PROVIDER: S-EPMC12797940 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature